Fennec Pharmaceuticals (TSX:FRX) Short Interest


TSX:FRX Fennec Pharmaceuticals Inc TSX:FRX
53 GF Score
Price C$15.00
GF Value C$14.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TSX:FRX vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Short Interest falls into.


TSX:FRX
53GF Score
Fennec Pharmaceuticals Inc TSX:FRX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$15.00 is trading 6.2% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

  • Short Interest:
  • GF Value™: C$14.13 vs. price of C$15.00 (6.2% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USARV41:Germany
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
53GF Score

Get the complete analysis for TSX:FRX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$15.00
Price
C$14.13
GF Value